Patents by Inventor Thierry Leveillard

Thierry Leveillard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210069346
    Abstract: The invention relates to the use of HNRNPC-expressing vectors for preventing and/or treating a tauopathy, such as Alzheimer's disease. The invention relates to methods for detecting a risk of developing a tauopathy such Alzheimer's disease in a patient, comprising the step of detecting the level of HNRNPC in a biological sample obtained from said patient.
    Type: Application
    Filed: November 6, 2020
    Publication date: March 11, 2021
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Hawa Camara
  • Patent number: 10857239
    Abstract: The invention relates to the use of HNRNPC-expressing vectors for preventing and/or treating a tauopathy, such as Alzheimer's disease. The invention relates to methods for detecting a risk of developing a tauopathy such Alzheimer's disease in a patient, comprising the step of detecting the level of HNRNPC in a biological sample obtained from said patient.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 8, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Hawa Camara
  • Publication number: 20200318138
    Abstract: The present invention relates to improved constructs comprising the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 8, 2020
    Inventors: Thierry LEVEILLARD, Najate AÏT-ALI MAAMRI, Fréderic BLOND, José-Alain SAHEL, Géraldine PUEL, Emmanuelle CLERIN
  • Publication number: 20200174023
    Abstract: The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.
    Type: Application
    Filed: December 12, 2019
    Publication date: June 4, 2020
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Celine Jaillard, Olivier Poch
  • Patent number: 10668129
    Abstract: The present invention relates to the synergistic combination of the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: June 2, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Thierry Leveillard, John Flannery, Xin Mei, Leah Byrne, José-Alain Sahel, Emmanuelle Clerin-Lachapelle, Junwei Sun, Jean Bennett, Jeannette Bennicelli
  • Publication number: 20190328846
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of retinal degenerative diseases. The inventors identified a new key actor of the mechanism underlying the protective role of RdCVF: 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2). The inventors showed that PFKFB2 is expressed by cones in a rod-dependant manner. In particular, they showed that its expression follows the viability of cones: its expression is lost in an animal model retinitis pigmentosa. The inventors accumulated evidences that PFKFB2, especially its kinase domain, is involved in the mechanism of action of RdCVF. More particularly they showed that transduction of a polynucleotide encoding for PFKFB2 increases cone survival. In particular, the present invention relates to a method of treating a retinal degenerative disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a polynucleotide encoding for the PFKFB2 kinase domain.
    Type: Application
    Filed: November 30, 2017
    Publication date: October 31, 2019
    Inventors: Thierry LEVEILLARD, Géraldine MILLET-PUEL, Alexandra Lyor BOUAZIZ
  • Publication number: 20190064189
    Abstract: The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.
    Type: Application
    Filed: October 2, 2018
    Publication date: February 28, 2019
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Celine Jaillard, Olivier Poch
  • Publication number: 20180179259
    Abstract: The invention relates to the use of HNRNPC-expressing vectors for preventing and/or treating a tauopathy, such as Alzheimer's disease. The invention relates to methods for detecting a risk of developing a tauopathy such Alzheimer's disease in a patient, comprising the step of detecting the level of HNRNPC in a biological sample obtained from said patient.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 28, 2018
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Hawa Camara
  • Patent number: 10004780
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD). In particular the present invention relates to RdCVFL polypeptide or polynucleotide for use in the treatment of AMD.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: June 26, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Therese Cronin, Leah Byrne, Ram Fridlich
  • Publication number: 20180153962
    Abstract: The present invention relates to the synergistic combination of the short and long Rod-Derived Cone Viability Factors and to methods for treating retinal degenerative diseases.
    Type: Application
    Filed: May 20, 2016
    Publication date: June 7, 2018
    Inventors: Thierry LEVEILLARD, John FLANNERY, Mei XIN, Leah BYRNE, José-Alain SAHEL, Emmanuelle CLERIN-LACHAPELLE, Sun JUNWEI, Jean BENNETT, Jeannette BENNICELLI
  • Publication number: 20170348434
    Abstract: The present invention relates to methods and composition for use in the treatment of retinal degeneration, in particular retinal degeneration due to retinal pigment epithelium dysfunction.
    Type: Application
    Filed: December 17, 2015
    Publication date: December 7, 2017
    Applicants: UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: THIERRY LEVEILLARD, CHRISTO KOLE, JOSE-ALAIN SAHEL
  • Publication number: 20170176417
    Abstract: The invention relates to compounds which activate the BASIGIN signalling pathway, preferably agonists of BASIGIN, for the treatment of neurodegenerative disorders.
    Type: Application
    Filed: February 20, 2017
    Publication date: June 22, 2017
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS
    Inventors: Ludivine Perrocheau, Alain Van Dorsselaer, Jose Alain Sahel, Thierry Leveillard
  • Patent number: 9575075
    Abstract: The present disclosure concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO:10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: February 21, 2017
    Assignees: INSERM (Institut National de la Sante et Recherche Medicale), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Thierry Leveillard, José-Alain Sahel, Céline Jaillard, Olivier Poch
  • Publication number: 20170014478
    Abstract: The present invention concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO: 10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.
    Type: Application
    Filed: July 8, 2016
    Publication date: January 19, 2017
    Inventors: Thierry Leveillard, José-Alain Sahel, Céline Jaillard, Olivier Poch
  • Publication number: 20160213701
    Abstract: The present invention relates to an isolated nucleic acid molecule comprising i) a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence and ii) a nucleotide sequence coding for a neurotrophic factor for use in the treatment of a retinal degenerative disease.
    Type: Application
    Filed: April 6, 2016
    Publication date: July 28, 2016
    Inventors: Jose-Alain SAHEL, Serge PICAUD, Thierry LEVEILLARD, Deniz DALKARA, Jens DUEBEL, Botond ROSKA
  • Publication number: 20150265676
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD). In particular the present invention relates to RdCVFL polypeptide or polynucleotide for use in the treatment of AMD.
    Type: Application
    Filed: October 17, 2013
    Publication date: September 24, 2015
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Therese Cronin, Leah Byrne, Ram Fridlich
  • Patent number: 8957043
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: February 17, 2015
    Assignees: Novartis AG, Universite de Strasbourg
    Inventors: Thierry Leveillard, Jose Alain Sahel, Saddek Mohand-Said, David Hicks
  • Publication number: 20150038557
    Abstract: The present invention relates to an isolated nucleic acid molecule comprising i) a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence and ii) a nucleotide sequence coding for a neurotrophic factor for use in the treatment of a retinal degenerative disease.
    Type: Application
    Filed: February 25, 2013
    Publication date: February 5, 2015
    Inventors: Jose-Alain Sahel, Serge Picaud, Thierry Leveillard, Deniz Dalkara, Jens Duebel, Botond Roska
  • Patent number: 8779093
    Abstract: This invention relates to methods and compositions for detection and treatment of neurodegenerative diseases. In particular, the invention relates to polypeptides that can protect against neuron degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: July 15, 2014
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Thierry Leveillard, Celine Jaillard, Jose-Alain Sahel
  • Publication number: 20130287738
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Application
    Filed: June 4, 2013
    Publication date: October 31, 2013
    Applicants: UNIVERSITE DE STRASBOURG, NOVARTIS AG
    Inventors: Thierry LEVEILLARD, Jose Alain SAHEL, Saddek MOHAND-SAID, David HICKS